Hereditary nephrotic syndrome: a systematic approach for genetic testing and a review of associated podocyte gene mutations

Geneviève Benoit · Eduardo Machuca · Corinne Antignac

Received: 17 December 2009 / Revised: 4 February 2010 / Accepted: 8 February 2010 / Published online: 24 March 2010
© IPNA 2010

Abstract Several genes have been implicated in genetic forms of nephrotic syndrome occurring in children. It is now known that the phenotypes associated with mutations in these genes display significant variability, rendering genetic testing and counselling a more complex task. This review will focus on the recent clinical findings associated with those genes known to be involved in isolated steroid-resistant nephrotic syndrome in children and, thereby, propose an approach for appropriate mutational screening. The recurrence of proteinuria after transplantation in patients with hereditary forms of nephrotic syndrome will also be discussed.

Keywords Hereditary glomerular disorders · Nephrotic syndrome · NPHS1 · NPHS2 · Steroid resistance

Introduction

The annual incidence of idiopathic nephrotic syndrome (NS) in children in the USA and in Europe has been estimated to be 1–3 per 100,000 children, with a cumulative prevalence of 16 per 100,000 children [1, 2]. About 90% of patients are steroid responsive [3], with a favorable long-term prognosis. The remaining 10% of children who do not respond to corticosteroids are particularly at risk for extrarenal complications of NS and the development of end-stage kidney disease (ESKD), which occurs in 30–40% of children with steroid-resistant NS (SRNS) after a follow-up of 10 years [4–6]. It has been suggested that steroid-sensitive NS, as well as a subset of SRNS, particularly those with a response to immunosuppressive agents and/or recurrence of proteinuria after kidney transplantation, have an underlying immune defect that may imply an unrecognized proteinuric circulating factor whose production seems to follow T cell dysfunction [7]. Some authors have found that the serum of patients with focal segmental glomerulosclerosis (FSGS) increases glomerular permeability to albumin when incubated with rat glomeruli in vitro [8, 9]. In contrast to these immune forms of NS, recent studies have shown that inherited structural defects of the glomerular filtration barrier are responsible of a large proportion of SRNS cases, thereby emphasizing the crucial role of the podocyte in the pathogenesis of glomerulopathies. Indeed, mutations in genes highly expressed in podocytes have been found in two thirds of patients presenting with SRNS in the first year of life [10]. To date, mutations in seven genes (NPHS1, NPHS2, CD2AP, PLCE1, ACTN4, TRPC6...
and INF2) [11–17] have been implicated in different forms of nonsyndromic SRNS. Nephrin, podocin and CD2AP, encoded by NPHS1, NPHS2 and CD2AP, respectively, are the main structural elements of the slit diaphragm [18]. Nephrin, a transmembrane protein of the immunoglobulin superfamily, interacts through its C-terminal part with podocin, a harpin-like scaffolding protein. Nephrin also interacts with CD2AP, an adapter protein found on the surface of T-cells and natural killer cells. PLC€, encoded by PLCE1, is a phospholipase that catalyses the hydrolysis of membrane phospholipids to generate the second messenger molecules inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG), thereby initiating intracellular pathways of cell growth and differentiation [19]. Additionally, PLC€ interacts with IQGAP-1 [16], a podocyte cell junction-associated protein and interacting partner of nephrin implicated in cell adhesion [20]. TRPC6 encodes the calcium channel TRPC6, which is localized in the membrane lipid supercomplex together with podocin and regulates mechanosensation sensed at the slit-diaphragm, while ACTN4 and INF2, encoding α-actinin-4 and a member of the formin family of actin-regulating proteins, respectively, are both involved in cytoskeletal dynamics.

Syndromic forms of SRNS, which are far less frequent, may be due to mutations in genes coding transcriptional factors (WT1, LMX1B) [21, 22], glomerular basement membrane components (LAMB2, ITGB4) [23, 24], lysosomal (SCARB2) [25] and mitochondrial (COQ2, PDSS2, MTTL1) [26–30] proteins or a DNA-nucleosome restructuring mediator (SMARCAL1) [31]. However, mutations in the WT1 gene, encoding the Wilms tumour 1 protein and typically leading to Denys–Drash syndrome (male pseudohermaphroditism, progressive glomerulopathy and Wilms tumour) or Frasier syndrome (male pseudohermaphroditism, progressive glomerulopathy and gonadoblastoma), can also cause isolated SRNS. In addition, mutations in LAMB2, encoding laminin-β2 and implicated in Pierson syndrome (a rare autosomal recessive disorder characterized by microcoria and other complex ocular abnormalities in association with NS of congenital onset), have been found in one family with isolated congenital NS (CNS).

MYH9, a podocyte-expressed gene encoding nonmuscle myosin IIA, has been identified as the disease-causing gene of the rare giant-platelet disorders, which may comprise Alport-like syndrome manifestations [32]. However, the particular interest of MYH9 resides in its role as a susceptibility gene in the development of kidney diseases. Indeed, it has recently been shown that common MYH9 genetic variants, although not directly pathogenic, confer a greater risk of FSGS and ESKD in African Americans [33–35].

Mutations in NPHS1 are responsible for most of cases of CNS [11], while mutations in NPHS2 are responsible for most of the early-onset SRNS cases [12]. Recent findings, however, including the identification of NPHS1 mutations in childhood-onset SRNS [36] or the implication of the NPHS2 p.R229Q variant in adult-onset NS [37], have broadened the spectrum associated with mutations in these genes. With the rapidly increasing number of genes known to be implicated in NS and the significant phenotypic variability observed, genetic testing is now a more complex task which needs to be based on different clinical information, including the type of renal histological lesions. Indeed, the approach taken during genetic testing will be different depending on the identification of diffuse mesangial sclerosis (DMS), a particularly severe renal lesion characterized by mesangial expansion and sclerosis that evolves toward obliteration of the capillary lumen and contraction of the glomerular tuft, or FSGS, a lesion characterized by sclerosis and foot process effacements in only some of the glomeruli and a part of each entire glomerulus.

This review will focus on the recent clinical findings associated with those genes known to be involved in isolated SRNS and, thereby, propose an approach for appropriate mutational screening. It has to be stressed that corticosterotherapy was not attempted in a significant number of patients with very early-onset NS and in patients already in ESKD at the time of the first medical evaluation, as the probability that they would have been refractory to therapy was high. Nevertheless, in order to enhance the clarity of our review, these patients are also classified as SRNS cases in this paper. Finally, the controversial issues concerning the recurrence of proteinuria post-transplantation in patients with hereditary forms of NS will be discussed.

Non-syndromic steroid-resistant nephrotic syndrome

Congenital nephrotic syndrome

Congenital nephrotic syndrome has been arbitrarily defined as the occurrence of NS in patients <3 months of age, although congenital actually means that the disease is present from birth. The most common type of CNS is congenital nephrotic syndrome of the Finnish type (CNF), a recessively inherited disorder characterized by massive proteinuria detectable at birth, a large placenta, marked edema and characteristic radial dilatations of the proximal tubules. These histological lesions are detected more frequently after 3 months of age, but they have also been identified in fetuses [38–41]. They are also considered to be an inconstant feature. Mesangial expansion and capillary obliteration are also evident in a significant proportion of CNF cases [42, 43]. It has been shown that hypoperfusion of glomerular and tubulointerstitial capillaries and rarefaction of the latter may explain the rapid development of
fibrosis in these patients [41]. The incidence of CNF in Finland has been estimated to be 1 in 8,200 live births [44], and a high incidence has also been reported among the Old Order Mennonites in Lancaster, Pennsylvania [45]. NPHS1 has been identified as the major gene involved in CNF [11] with the Fin-major (p.L41fsX91) and Fin-minor (p.R1109X) mutations accounting for 78 and 16% of the mutated alleles among Finnish patients, respectively [11]. The Fin-major and Fin-minor mutations have rarely been found in other ethnic groups. Among non-Finnish cases with a CNF phenotype, the NPHS1 mutation detection rate approaches 66% [46]. To date, more than 140 different NPHS1 mutations have been identified, comprising nonsense, missense, frameshift insertion/deletion and splice-site mutations.

It has now become clear that not all NPHS1 mutations cause severe CNS or a severe clinical course. In one study involving patients bearing the p.R1160X NPHS1 mutation in the homozygous state (resulting in a truncated protein lacking the C-terminal 82 amino acids implicated in the interaction with podocin), about half of the patients had a milder phenotype, in that although they presented with severe NS in the first 3 months of life, their further renal course was relatively benign with spontaneous partial or complete remission in childhood [47]. Histological findings, where available, were consistent with CNF. The clinical variability was apparently influenced by gender, as the majority of the mildly affected cases were female.

Although NPHS1 is the main gene that has been identified in patients presenting NS in the first 3 months of life, it has also been shown that CNS may be caused by mutations in several other genes, including NPHS2. Mutations in this latter gene have been detected in patients with a classically severe CNF phenotype [47] and have been shown to account for up to 51% of all mutations in Central European patients with CNS [10]. It has to be pointed out that the median age at onset of CNS in the latter study was relatively late (median age 4 weeks), which may induce a bias toward a greater prevalence of NPHS2 mutations instead of NPHS1 mutations. Indeed, in our large worldwide cohort of CNS patients, which mostly presented proteinuria in the first few days of life, NPHS1 mutations were detected in more than half of all cases (unpublished data). Mutations in the PLCE1 gene [16, 48–50], and the WT1 gene [48, 51–55] have also been detected in patients presenting isolated CNS with DMS on renal histology; mutations in these two genes will be discussed in more detail in the next section.

These observations suggest that, for patients presenting nonsyndromic CNS, the NPHS1 gene should be tested first in those presenting NS shortly after birth as well as in those with typical proximal tubular radial dilatation. Molecular analysis of NPHS2 should be the next step whenever mutations in NPHS1 are not detected. Patients presenting later in the congenital period (particularly if renal biopsy shows FSGS or minimal glomerular changes) should probably be initially screened for NPHS2 mutations, followed by NPHS1. In cases for which renal histological findings are available and DMS is determined, genetic testing of the WT1 and PLCE1 genes should initially be performed.

Infantile nephrotic syndrome and childhood nephrotic syndrome

The term infantile NS has been proposed for patients that develop NS between the ages of 4 and 12 months. NPHS2 mutations are responsible for most of these cases [12], and they have also been found in a significant proportion of patients with childhood-onset SRNS. Mutations in this gene occur in about 40% of familial and 6–17% of sporadic SRNS cases (Table 1) [55–59]; patients typically present NS from birth to 6 years of age and reach ESKD before the end of their first decade of life [10, 55–57, 59, 60]. Renal histology of such patients reveals either minimal glomerular changes (if biopsied early) or FSGS. The identification of mutations is important as it may enable the treating physicians to avoid (or discontinue) prescribing immunosuppressive therapies for these patients, sparing them the significant side-effects associated with these drugs. Indeed, considering that access to genetic testing is now easier than it has been in the past and that sequencing of the NPHS2 gene is relatively fast as it comprises only eight exons, screening for NPHS2 mutations in patients presenting the renal phenotype described above should be performed prior to the initiation of additional—potentially deleterious—therapy. To date, more than 100 pathogenic NPHS2 mutations and 25 variants of unknown significance have been reported, including a full spectrum of protein-truncating nonsense and frameshift mutations, splice-site variants and missense changes, involving all coding exons. Patients with frameshift, nonsense or the homozygous p.R138Q missense mutations manifest symptoms at a significantly earlier age [57, 59]. The p.R138Q mutant, which accounts for up to 32% of all mutant alleles, is retained in the endoplasmic reticulum (ER), where it essentially functions as a null allele and fails to recruit nephrin to lipid rafts [61, 62]; this may explain the phenotype severity associated with this mutation. In contrast, the p.R229Q variant has been shown to lead to late-onset NS [37, 63], when found in association with one pathogenic NPHS2 mutation. This variant represents the most frequently reported nonsynonymous NPHS2 variant in Caucasians and is particularly common among Europeans, in whom the observed frequency of heterozygotes ranges from 0.03 to 0.13 [55, 59, 63–66]. In vitro studies have
End-stage kidney disease

ESKD, End-stage kidney disease

Table 1 Rate of detection of two pathogenic *NPHS2* mutations in SRNS cases

| References       | Sporadic cases (n) | Percentage | Familial cases (n) | Percentage | Age at onset (years) | Age at ESKD (years) |
|------------------|--------------------|------------|--------------------|------------|----------------------|---------------------|
| Caridi et al. [56] | 14/120             | 11.7       | –                  | –          | 2.3                  | 9.2                 |
| Weber et al. [59]  | 11/172             | 6.4        | 31/81              | 38.3       | 3.4                  | –                   |
| Berdeli et al. [60]| 41/254             | 16.1       | 9/32               | 28.1       | 3.8                  | 9.4                 |
| Hinkes et al. [57] | 64/381             | 16.8       | 9/23               | 39.1       | 2.6                  | –                   |

ESKD, End-stage kidney disease

*a* Subgroups of patients in this study had been included in the analysis by Ruf et al. (2004) [55] and Hinkes et al. (2007) [10]

*b* Represents families with only one affected member

*c* Defined as families with either two or more affected children, or one (or more) affected individual in consanguineous families

It has recently been shown that mutations in *NPHS1* also account for a nonnegligible proportion of infantile and childhood-onset SRNS cases. Two studies found *NPHS1* mutations in 7–14% of the patients presenting SRNS at least 3 months after birth [age at onset of NS in mutated patients 0.5–8 years (mean 3 years) and 0.7–27 years (mean 8 years, respectively)] [36, 67] with minimal glomerular changes, FSGS or mesangio-proliferative lesions on renal biopsies. These percentages are, however, overestimated as these studies included patients for which mutations in the *NPHS2* gene were excluded. The presence of at least one “mild” mutation likely explains the later onset and milder course of the disease among these cases. As such, missense mutants retaining their abilities to traffic in the cell properly, a splice-site mutation allowing some correct splicing and a protein-truncating mutation involving only the very C-terminus of the protein may be designated as “mild” because partial function of nephrin is maintained. Similarly, NS with spontaneous partial remissions and repeated relapses concurrently with respiratory infections has been described in two siblings bearing nephrin mutations [68]. Both infants, who presented NS at birth and at 10 months of age, respectively, were compound heterozygous for the p.C265R and p.V822M mutations with minimal glomerular changes observed on the renal biopsy. The p.C625R mutant protein was predominantly trapped within the ER, while the p.V822M variant protein reached the plasma membrane, probably explaining the milder phenotype seen in these patients. Modifier genes or environmental factors may also play a role in renal phenotype variability, as the same two *NPHS1* mutations (p.R827X and p.R976S) have been identified in one adult patient diagnosed with FSGS at 27 years of age with unimpaired renal function after 2 years of follow-up [67] and in one patient with infantile-onset NS [36].

In addition to *NPHS2* and *NPHS1*, *PLCE1* is involved in some infantile and childhood-onset SRNS cases and is the main gene causing DMS. *PLCE1* mutations have been detected in 28.6% of families with isolated DMS [48], with the clinical onset of reported cases of DMS varying from few days of life to 4 years of age [16, 48–50] and all patients having truncating mutations. The results of one study suggested that homozygous *PLCE1* missense mutation (found in only two siblings) may lead to a milder phenotype of FSGS with a relatively late age at onset of proteinuria (in this study, 8.8 years and 2.0 years, respectively). However, in our cohort, truncating or missense mutations were detected in both DMS and FSGS patients, leading to a similar renal evolution (in press). Nevertheless, *PLCE1* mutations remain an infrequent cause of FSGS: a Dutch study did not find *PLCE1* mutations in 19 cases of childhood-onset FSGS [69] nor were mutations in this gene found in 69 families (median age of disease onset 26 years, range 1–66 years) with idiopathic or hereditary FSGS [70].

*WT1* mutations may account for about 9% of patients with nonfamilial isolated SRNS [54], and they have been identified in patients with isolated DMS, with a clinical onset varying from a few days of life up to 2 years of age, as well as in isolated FSGS (1–14 years of age) [48, 51, 54, 71–74]. Almost all cases were those of phenotypically female patients, and the mutations occurred mainly in exons 8 and 9, which code for zinc finger domains 2 and 3, respectively [54].

Based on these observations, *NPHS2* followed by *NPHS1* remain the first genes to be tested in nonsyndromic patients presenting SRNS associated with minimal glomerular changes/FSGS in the infantile or childhood period. In the remaining patients with the same histological lesions, genetic testing for *WT1* mutations (exons 8 and 9 in phenotypically female patients) should be performed, while screening for *PLCE1* mutations may be considered in some cases (mainly in familial cases). However, the probability of identifying a *PLCE1* mutation in this patient category is low, and the molecular analysis of this large 33-exon gene is expensive and time-consuming; thus, these factors should be taken into account in the decision on genetic screening. In cases of isolated DMS, *PLCE1* is the most frequently involved gene...
but, for cost-effective reasons, genetic testing of exons 8 and 9 of WT1 (especially in phenotypically female patients) may be performed prior to PLCE1.

Mutations in the CD2AP, ACTN4 and TRPC6 genes have been anecdotally reported in young patients, precluding any suggestion of systematic mutational screening of these genes in children—unless there is an autosomal dominant familial history of FSGS, which would warrant the molecular analysis of the two latter genes. To date, the clear pathogenic implication of CD2AP in NS has been shown in only one study: a homozygous mutation (p.R612X) was identified in a 10-month-old nephrotic child who presented global glomerular sclerosis on renal biopsy; the truncated protein displayed a dramatic reduction of actin binding efficiency in vitro [75]. Heterozygous expression of the CD2AP mutation in both parents did not lead to any kidney pathology. Nevertheless, the insignificant role of recessive CD2AP mutations has been emphasized in a recent study that did not find homozygous CD2AP mutations in a cohort of 42 children (35 families) with SRNS for whom the NPHS1, NPHS2, PLCE1 and WT1 mutations had been previously excluded [76]. On the other hand, carrying a heterozygous mutation in the CD2AP gene has been reported to be a predisposing factor towards developing FSGS. To date, five different CD2AP heterozygous mutations have been identified in pediatric (and adult) FSGS patients [14, 69, 77], associated with reduced expression of CD2AP or defective CD2–CD2AP interaction in lymphocytes and down-regulation of CD2AP, nephrin and podocin glomerular expression on kidney biopsies. Unfortunately, as complete segregation data are not available in all of these cases, neither penetrance nor inheritance can be assessed with certainty. In addition, heterozygous CD2AP mutations have been found in clinically unaffected patients. Therefore, there is still some doubt surrounding the direct causal link between heterozygous CD2AP mutations and FSGS; it is possible that CD2AP haploinsufficiency has a role in the susceptibility to develop glomerular disorders instead [14]. Mutations in ACTN4 and TRPC6 have been implicated in the rare autosomal dominant FSGS and account for approximately 4 and 6% of familial FSGS, respectively [78, 79]. Patients with ACTN4 mutations usually present proteinuria in their teenage years or later, with a slow progression to ESKD in their fifth decade of life [13, 80]. Similarly, disease onset in patients with TRPC6 mutations has initially been reported to vary between 17 and 57 years [15, 81]. However, de novo ACTN4 mutations have been reported in three children (two families) from 3 to 5 years of age who presented rapid progression to chronic kidney disease/ESKD [78, 82]. We have detected a de novo TRPC6 missense mutation in one patient that presented NS secondary to FSGS at 6.5 years of age and reached ESKD few months later (unpublished data), while TRPC6 missense mutations have also recently been identified in two FSGS patients with disease onset at 7 and 9 years of age, respectively; the first patient showed a partial response to cyclosporine A and mycophenolate mofetil (MMF), and the mutation was also found in her asymptomatic 40-year-old father [79, 83]. Therefore, similarly to CD2AP heterozygous mutations, TRPC6 may contribute to glomerular disease in a multi-hit setting. Finally, mutations in INF2 have also been found very recently in 11 families presenting moderate proteinuria and FSGS lesions in early adolescence or adulthood, thereby explaining about 12% of familial FSGS cases with an apparent autosomal dominant inheritance [17]. If the significant role of INF2 as a genetic cause of NS is confirmed by further studies, screening for mutations in this gene will also need to be recommended in the near future in patients with an autosomal dominant familial history of FSGS.

A summary of the mutational screening approach suggested in patients with nonsyndromic SRNS is given in Fig. 1.

Genetic counselling

Genetic counselling should be offered to any patient and his/her family affected with an inherited disorder. Information that needs to be shared will vary according to the mutations found. Therefore, clinicians should be aware of the specific aspects that should be discussed with patients, particularly in cases involving mutations in the NPHS2, WT1 and PLCE1 genes.

In SRNS patients with NPHS2 mutations who are considering having children, genetic testing for the p.R229Q variant, which is found in a high frequency in some populations, should be proposed to their asymptomatic spouses. Indeed, if the p.R229Q variant is identified in the spouse, there is up to a 50% risk of disease (a juvenile or adult-onset form of SRNS) transmission to their progeny. In addition, heterozygous carriers, such as patient siblings, also have a non-negligible risk of disease transmission to their children if the spouse carries the p.R229Q variant.

Special considerations also apply for patients bearing mutations in the WT1 gene. Although most of the WT1 mutations are de novo, XX female patients with isolated DMS/FSGS secondary to the WT1 mutation have normal genital development and may become pregnant; therefore, these patients have a 50% risk of transmitting the mutated gene to their children. The phenotype of the progeny will depend on its karyotype; a 46 XY child may develop complete Denys–Drash syndrome or Frasier syndrome, while a 46 XX child will not present ambiguous genitalia. A case report well illustrates the clinical implications of familial WT1 mutation transmission: the index case’s
mother had typical FSGS (clinical onset at 6 years of age) with normal external and internal genitalia, while the index case presented with early DMS and XY pseudohermaphroditism [73]. Therefore, a female bearing a WT1 mutation and planning to be pregnant should be informed that her children may develop a phenotype significantly different (and more severe) from her phenotype.

Variability in the renal phenotype should also be discussed with families in which PLCE1 mutations are present. Indeed, it has been suggested that PLCE1 mutations are not always sufficient to cause DMS [49] as a same homozygous truncating mutation has been found in an asymptomatic father and his affected children with DMS. We have also identified three asymptomatic adults from three unrelated families bearing homozygous mutations with at least one affected sibling haploidentical to the unaffected cases (in press). We may speculate that modifier genes or environmental factors play a role in the renal phenotype variability observed in individuals bearing PLCE1 mutations. These observations need to be considered in the ensuing discussion with the patients on renal prognosis.

Finally, prenatal diagnosis should be offered to families with a known risk for severe NS, such as CNS, and to patients for whom elevated measurements of alpha-fetoprotein (AFP) in the maternal serum and amniotic fluid have been detected. In the first scenario, it has to be stressed that although results can be obtained relatively quickly when the causative mutations have previously been identified in the family, prenatal genetic testing may be more time-consuming in other cases. This highlights the importance of referring these families to a geneticist—ideally before conception or, if not possible, very early during pregnancy. An early genetic consultation may not only provide the background for a discussion of the risk of disease transmission and ethical questions related to medical termination of pregnancy (MTP), it may also allow the appropriate diagnostic procedures (trophoblastic biopsy or amniocentesis) to be planned within an adequate timeframe. In the second scenario involving families in which elevated AFP have been unexpectedly found, genetic counselling is also required as this finding may suggest CNS secondary to nephrin mutations (assuming that anomalies such as fetal anencephaly or omphalocoele have been ruled out). However, this diagnosis needs to be confirmed by mutation analysis prior to considering MTP as AFP elevations have been observed in NPHS1 heterozygous fetal carriers and in a fetus with Denys–Drash syndrome [84, 85].

**Recurrence of proteinuria after renal transplantation**

Most patients with genetic forms of NS are resistant to immunosuppressive agents [10, 55, 86] and are therefore at high risk of ESKD [4–6]; renal transplantation may be the treatment of choice in these cases. In patients with SRNS requiring transplantation, the recurrence of NS in kidney grafts raises significant concerns as it is observed in approximately 30–50% of FSGS cases [87–89]. However, in contrast to patients with an immune form of NS, those with an inherited structural defect of the glomerular filtration barrier represent a subset of patients for whom the primary disease cannot a priori recur. Surprisingly,

**Fig. 1** Genetic approach in children with isolated steroid-resistant nephrotic syndrome. Asterisk In patients with minimal glomerular change/focal segmental glomerulosclerosis (MGC/FSGS) who present in the congenital period, those with nephrotic syndrome (NS) onset very shortly after birth should probably be screened first for NPHS1 mutations followed by NPHS2 mutations. Cross Only nonsyndromic forms of NS associated with WT1 mutations are included. Most of the WT1 mutations in patients with isolated steroid-resistant NS (SRNS) have been found in phenotypically female patients. PT, proximal tubules, DMS diffuse mesangial sclerosis, AR autosomal recessive, AD autosomal dominant.

| ONSET | RENAL HISTOLOGY | GENE |
|-------|-----------------|------|
| CONGENITAL | Radial dilatation of PT | NPHS1 |
| INFANTILE | MGC/FSGS | NPHS2' → NPHS1 |
| CHILDHOOD | MGC/FSGS | WT1'/PLCE1 |
| JUVENILE AND ADULT | FSGS | NPHS2 → NPHS1 → WT1 → PLCE1 |

| | | |
| --- | --- | --- |
| AR or Sporadic | NPHS2 (p.R229Q) | |
| AD | TRPC6/ACTN4/INF2? | |
recurrence of proteinuria post-transplantation has been reported in some patients bearing mutations in the \textit{NPHS1}, \textit{NPHS2}, \textit{ACTN4} and \textit{WT1} genes \cite{55, 59, 78, 90–95}, and the mechanism of recurrence remains unsolved for a significant proportion of these cases.

The most often provided explanation for recurrence of NS is the development of antibodies. In a study of cases with \textit{NPHS1} Fin-major/Fin-major mutations (mutations leading to the absence of nephrin in the native kidney), recurrence occurred in 25\% of patients at a mean time of 12 months post-transplantation (range 5 days to 48 months), and antinephrin antibodies were detected in almost half of these cases \cite{96}. Because recurrence in these patients may be considered as an immune process against the “neo-antigen” nephrin present in the graft, it is not surprising that treatment with steroids, cyclophosphamide and plasmapheresis may lead to remission; however, the percentage of graft loss remains significant \cite{96, 97}. On the other hand, antipodocin antibodies have never been found \cite{59, 90, 91}. As podocin is a harpin-like protein with two intracellular ends but no extracellular domain, one may speculate that antibodies against this “hidden” protein cannot be produced. This hypothesis may also explain the absence of post-transplantation recurrence in nephrophtisis or cystinosis, two diseases for which the involved proteins are only intracellular. In addition, renal transplantation should stimulate the production of antibodies only when mutations lead to the absence of the encoded protein (or at least a part of it) in the native kidney. Therefore, the development of antibodies cannot explain the recurrence of proteinuria in some patients with \textit{NPHS2} missense mutations as well as in the reported cases of two children with either a missense (p.W54R) \textit{ACTN4} mutation \cite{78} or a splice-site (IVS9 + 4C>T) \textit{WT1} mutation \cite{95}.

Data on the risk of proteinuria recurrence in patients with podocin mutations may be confusing as patients without true pathogenic mutations were included in some studies. In the reports of Bertelli et al., post-transplantation recurrence was stated to occur in five of 13 (38\%) patients with homozygous (n=9) or heterozygous (n=4) podocin mutations compared to 15 of 40 (44\%) non-\textit{NPHS2} FSGS patients \cite{91}. However, among the five patients described as having \textit{NPHS2} mutations and recurrence, three had only heterozygous variants for which a pathogenic role is very unlikely (the Polyphen software program predicted the p.S221T variant would be benign, and the p.P20L variant is clearly a polymorphism \cite{55}). When only patients with two pathogenic \textit{NPHS2} mutations are taken into account, the risk of recurrence significantly decreases, thereby being more in agreement with the low recurrence rate of 3–8\% reported in other studies \cite{55, 59} (Table 2). Finally, it has also to be stressed that several etiologies, including drug side-effects, may explain the occurrence of proteinuria after transplanta-

\begin{table}[h]
\centering
\begin{tabular}{|l|c|c|c|c|c|c|c|c|c|}
\hline
\textbf{References} & \textbf{Mutation} & \textbf{Recurrence, n(\%)} & \textbf{Timing of recurrence PT} & \textbf{Outcome} & \textbf{Permeability factor (Pab)} & \textbf{Anti-podocin antibody} & \textbf{Treatment} & \textbf{Outcome} & \textbf{Seq}\textbf{Permeability factor (Palb)} \\
\hline
Weber et al. \cite{59} & p.R138X-p.R138X & 1/32 (3.1) & 2 years & FSGS & ND & ↓ GFR & Negative & ND & ND \\
Ruf et al. \cite{55} & p.L347X-p.K126N & ND & ND & ND & ND & ND & ND & ND & ND \\
Bertelli et al. \cite{91} & p.R138Q-p.R138Q & 2/9 (22.2) & 10 days & ND & Good & High & Negative & PL + Cyl & Good \\
& p.R138Q-p.R138Q & 3/100 days & FSGS & ND & Good & High & Positive & PL + Cyl & Good \\
& p.L347X-p.L347X & 2/24 (8.3) & 7 days & ND & Good & High & Positive & Pred Pk & Good \\
& p.L347X-p.L347X & 1/32 (3.1) & 2 years & FSGS & ND & ↓ GFR & Negative & PL & Good \\
& p.R138Q-p.R138Q & ND & ND & ND & ND & ND & ND & ND & ND \\
& p.R138Q-p.R138Q & ND & ND & ND & ND & ND & ND & ND & ND \\
& p.L347X-p.L347X & Case report & Case report & Case report & Case report & Case report & Case report & Case report & Case report \\
& p.R138Q-p.R138Q & 10 years & PL & ↓ GFR & Negative & Normal & PL & PL & PL \\
& p.R138X-p.R138X & 4 years & FSGS & PL & ↓ GFRd & Negative & Normal & PL & PL \\
& p.R138Q-IVS 4-1 G>T & Case report & Case report & Case report & Case report & Case report & Case report & Case report & Case report \\
Höcker et al. \cite{94} & p.R138Q-IVS 4-1 G>T & Case report & Case report & Case report & Case report & Case report & Case report & Case report & Case report \\
Becker-Cohen et al. \cite{90} & p.R138X-p.R138X & Case report & Case report & Case report & Case report & Case report & Case report & Case report & Case report \\
\hline
\end{tabular}
\caption{Recurrence of proteinuria on renal graft in patients with homozygous or compound heterozygous \textit{NPHS2} mutations}
\end{table}
tion, even in patients with inherited SRNS. One possible example is the reported case of an 18-year-old female patient, compound heterozygous for NPHS2 mutations, with recurrence 10 years post-transplant after conversion from cyclosporine A to sirolimus; however, one may also argue that proteinuria was induced by sirolimus and/or that the FSGS lesions documented on the graft biopsy were secondary to the long course of cyclosporine administration [94]. Considering these cases as “true” recurrence may lead to overestimation of the risk.

 Altogether, the risk of recurrence in patients bearing two pathogenic NPHS2 mutations is low. The absence of a clear explanation for post-transplantation recurrence in these cases raises interesting pathophysiological questions that should be addressed in further studies. Indeed, the determination of high serum glomerular permeability activity in two patients with homozygous NPHS2 mutations at the time of recurrence episodes may suggest the additional potential role of a circulating permeability factor in some cases of hereditary SRNS [93]. Further studies on the impact of donor-dependant genetic factors on renal graft function are also warranted, as it has been suggested that variants in the donor NPHS2 promoter may affect podocin expression, thereby determining the outcome of proteinuria [98, 99], and that potential donor-recipient MYH9 genotype interactions may influence the occurrence of NS after pediatric kidney transplantation [100].

 Finally, before considering living related donor transplantation in cases with inherited SRNS, particular issues should be discussed with the families. It is worth reporting that three patients (bearing the NPHS2 p.L347X [55, 92], p.R138X [59] and p.R138Q-IVS 4–1 G>T [94] mutations, respectively, in the homozygous or compound heterozygous state) receiving a kidney from their respective mother, who was an obligatory healthy heterozygous carrier, presented recurrence of NS after transplantation. Despite recurrence, renal outcome was favourable in most of these cases. One may speculate that the graft may be more susceptible for the late development of FSGS and that the donor with one kidney may be at risk of developing FSGS. However, the number of recurrence cases (which remains low in the literature) should be compared to the total number of transplants performed before clear guidelines are drawn on living related donor transplantation in genetic forms of SRNS.

 In conclusion, genetic disorders account for most of the cases of NS that start within the first year of life and a considerable proportion of those with childhood-onset NS. It is important to differentiate between NS due to an underlying genetic defect and other cases of SRNS, as the pathophysiology, clinical course and response to therapy are different. The identification of mutations may also modify the approach taken to counselling patients, particularly on the risk of recurrence after renal transplantation. Although the clinical course is dependant on the gene(s) involved, significant phenotypic variability has been demonstrated in patients bearing mutations in the same gene and even in patients bearing the same mutation. Therefore, a systematic step-wise approach for appropriate mutational screening is required in patients with SRNS. When a hereditary disorder is suspected, at least three main criteria should be considered in order to better determine the appropriate(s) gene(s) to test: (1) age at onset of NS, (2) presence of extrarenal abnormalities and (3) type of renal histological lesions. Careful clinical and biochemical investigations, including a search for ocular abnormalities, ambiguous genitalia/male pseudohermaphroditism, skeletal abnormalities, neurological symptoms and thrombocytopenia, need to be performed prior to the initiation of genetic testing. The country of origin of the patients may also orient the genetic testing; indeed, while NPHS1 mutations are more frequently found in Finland, the prevalence of NPHS2 mutations in SRNS cases is higher in Europeans and Turkish patients than in Asian children [57, 101]. Nevertheless, for some patients with SRNS, genetic testing will fail to detect mutations in the known genes involved in NS. Although an immune etiology or a complex genetic inheritance is probably responsible for most of these cases, the ongoing identification of novel gene loci in families with SRNS indicates that there are additional genetic causes of SRNS that still need to be identified. Further promising strategies, including high-throughput sequencing and copy number analysis-based strategies, may lead to the identification of novel genes in the near future.

References

1. International Study on Kidney Disease in Children (1978) Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the international study on kidney disease in children. Kidney Int 13:159–165
2. McKinney PA, Feltbower RG, Brocklebank JT, Fitzpatrick MM (2001) Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK. Pediatr Nephrol 16:1040–1044
3. International Study on Kidney Disease in Children (1981) The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr 98:561–564
4. Cattran DC, Rao P (1998) Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 32:72–79
5. Mendoza SA, Reznik VM, Griswold WR, Krensky AM, Yorgin PD, Tune BM (1990) Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents. Pediatr Nephrol 4:303–307
6. Mekahli D, Liutkus A, Ranchin B, Yu A, Bessenay L, Girardin E, Van Damme-Lombaerts R, Palcoux JB, Cachat F, Lavocat MP, Bourdat-Michel G, Nobili F, Cochat P (2009) Long-term
outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study. Pediatr Nephrol 24:1525–1532.

7. Bruneau S, Dantal J (2009) New insights into the pathophysiology of idiopathic nephrotic syndrome. Clin Immunol 133:13–21.

8. Savin VJ, Sharma R, Lovell HB, Welling DJ (1992) Measurement of albumin reflection coefficient with isolated rat glomeruli. J Am Soc Nephrol 3:1260–1269.

9. Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Arteo M, Vinci E, Gubler MC, Niaudet P, Antignac C (2000) NPHS2, encoding the glomerular protein podocin, is mutated in congenital nephrotic syndrome. Mol Cell 1:575–582.

10. Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, Hawkins AF, Daskalakis N, Kwan SY, Ebersviller S, Burchette AB, Navas P, DiMauro S, Montini G (2005) Infantile encephalopathy with ocular atrophy, growth retardation, and hepatic fibrosis. Pediatr Neurol 33:17–23.

11. Kestila M, Lenkkeri U, Mannikko M, Lamerdin J, McCready P, Putaala H, Ruotsalainen V, Morita T, Nissinen M, Herva R, Kashtan AM, Putalai H, Ruotsalainen V, Morita T, Nissinen M, Herva R, Kashtan C, spectrins, and alpha-actinin are components of the nephrin multiprotein complex. Proc Natl Acad Sci USA 102:9814–9819.

12. Lehtonen S, Ryan JJ, Kudlicka K, Iino N, Zhou H, Farquhar MG (1998) Mutations in LMIC1 cause abnormal skeletal patterning and renal dysplasia in nail patella syndrome. Nat Genet 19:47–50.

13. Kaplan JM, Kim SH, North KN, Attanasio M, O'Toole JF, Hasselbacher K, Hangan D, Ozaltin F, Zender M, Hildebrandt F (2007) Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrix 119:e907–e919.

14. Kestila M, Lenkkeri U, Mannikko M, Lamerdin J, McCready P, Putaala H, Ruotsalainen V, Morita T, Nissinen M, Herva R, Kashtan C, spectrins, and alpha-actinin are components of the nephrin multiprotein complex. Proc Natl Acad Sci USA 102:9814–9819.

15. Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, Hawkins AF, Daskalakis N, Kwan SY, Ebersviller S, Burchette AB, Navas P, DiMauro S, Montini G (2005) Infantile encephalopathy with ocular atrophy, growth retardation, and hepatic fibrosis. Pediatr Neurol 33:17–23.

16. Hinkes BG, M, Gubler MC, Niaudet P, Antignac C (2000) NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 24:349–354.

17. Kaplan JM, Kim SH, North KN, Rennke H, Correa LA, Tong H, Mathis BJ, Rodriguez-Perez JC, Allen PG, Beggs AH, Pollak MR (2000) Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 24:251–256.

18. Kim JM, Wu H, Green G, Winkler CA, Kopp JB, Miner JH, Unanue ER, Shaw AS (2003) CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science 300:1298–1300.

19. Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, Hawkins AF, Daskalakis N, Kwan SY, Ebersviller S, Burchette JL, Pericak-Vance MA, Howell DN, Vance JM, Rosenberg PB (2005) A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 308:1801–1804.

20. Hinkes BG, Gubler MC, Niaudet P, Antignac C (2006) NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 24:349–354.

21. Mollet J, Giurgea I, Schlemmer D, Dallner G, Chretien D, Delahodde A, Bacq D, de Lonlay P, Munnich A, Rotig A (2007) Del20, a polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet 79:102–110.

22. Dreyer SD, Zhou G, Baldini A, Winterpach A, Zabel B, Cole W, Unanue ER, Shaw AS (2003) CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science 300:1298–1300.
Mutations in MYH9 result in the May–Hegglin anomaly, and Fechtler and Sebastian syndromes. The May–Hegglin/Fechtler syndrome consortium. Nat Genet 26:103–105

33. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR, Funk NE, Sadler JH, Weir MR, Abboud HE, Adler SG, Divers J, Iyengar SK, Freedman BI, Kimmel PL, Knowler WC, Kohn OF, Kramp K, Leehey DJ, Nicholas SB, Puffenberger EG, Schilling JR, Sedor JR, Thornley-Brown D, Winkler CA, Smith MW, Parekh RS (2008) MYH9 is associated with nonidiopathic end-stage renal disease in African Americans. Nat Genet 40:1185–1192

34. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bostrom MA, Comeau ME, Baudouin V, Abel L, Grunfeld JP, Antignac C (2009) Novel mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Pediatr 15:722–732

35. Lamerdin J, Gribouval O, Niaudet PM, Antignac C, Kikuchi H, Ikeda M, Kikuchi H, Hata J, Honda M, Coresh J, Patterson N, Tandon A, Powe NR, Fink NE, Sadler JM, Winkler CA (2008) MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 40:1175–1184

36. Lenkkeri U, Mannikko M, McCready P, Lamerdin J, Gribouval O, Niaudet PM, Antignac C, Khawaja CE, Homberg C, Olsen A, Kestila M, Tryggvason K (1999) Structure of the gene for congenital nephrotic syndrome of the Finnish type (NPHS1) and characterization of mutations. Am J Hum Genet 64:51–61

37. Koziell A, Grech V, Hussain S, Lee G, Lenkkeri U, Tryggvason K, Scambler P (2002) Genotype/phenotype correlations of NPHS1 and NPHS2 mutations in nephrotic syndrome advocate a functional inter-relationship in glomerular filtration. Hum Mol Genet 11:379–388

38. Gribouval O, Niaudet PM, Antignac C, Hashmi S, Ulmer F, Cleper R, Rettenge R, Chakravarti A, Winkler CA (2008) Mutations in PLEC1 are a major cause of isolated diffuse mesangial sclerosis (IDMS). Nephrol Dial Transplant 23:1291–1297

39. Gilbert RD, Turner CL, Gibson J, Bass PS, Haq MR, Cross E, Bunyan DJ, Collins AR, Tapper WJ, Needell JC, Dell B, Morton NE, Temple IK, Robinson DO (2009) Mutations in phosphopase C epsilon 1 are not sufficient to cause diffuse mesangial sclerosis. Kidney Int 75:415–419

40. Ismaili K, Pawtowski A, Boyer O, Wissing KM, Jansen F, Hall M (2009) Genetic forms of nephrotic syndrome: a single-center experience in Brussels. Pediatr Nephrol 24:287–294

41. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bostrom MA, Comeau ME, Baudouin V, Abel L, Grunfeld JP, Antignac C (2008) Congenital nephrotic syndrome of Finnish type. Kidney Int 75:1099–1107

42. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bostrom MA, Comeau ME, Baudouin V, Abel L, Grunfeld JP, Antignac C (2008) Nephrotic syndrome associated with the R229Q variant. Kidney Int 75:1099–1107

43. Kaukinen A, Kuusniemi AM, Lautenschlager I, Jalanko H (1976) Congenital nephrotic syndrome of Finnish type. Kidney Int 75:1099–1107

44. Kaukinen A, Lautenschlager I, Helin H, Karikoski R, Jalanko H (1981) Renal pathology of fetal congenital nephrosis. Acta Pathol Microbiol Scand [A] 89:63

45. Kestila M, Tryggvason K (1999) Structure of the gene for myosin heavy chain 9 gene (MYH9). Acta Pharm Scand 71:435–445

46. Knollinger U, Leoni M, Delgado ML, Vlahov D, Winkler CA (2008) MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 40:1175–1184

47. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bostrom MA, Comeau ME, Baudouin V, Abel L, Grunfeld JP, Antignac C (2008) Congenital nephrotic syndrome of Finnish type (NPHS1). Nephrol Dial Transplant 23:1291–1297.
basis of the functional podocin-nephrin complex: mutations in the NPHS2 gene disrupt nephrin targeting to lipid raft micro-domains. Hum Mol Genet 12:3397–3405

62. Roselli S, Moutkine I, Gribouval O, Benmerah A, Antignac C (2004) Plasma membrane targeting of podocin through the classical exocytic pathway: effect of NPHS2 mutations. Traffic 5:37–44

63. Tsukaguchi H, Sudhakar A, Le TC, Nguyen T, Yao J, Schimmer JA, Schachter AD, Poch E, Abreu PF, Appel GB, Pereira AB, Kalluri R, Pollak MR (2002) NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele. J Clin Invest 110:1659–1666

64. Franceschini N, North KE, Kopp JB, McKenzie LI, Winkler C (2006) NPHS2 gene, nephrotic syndrome and focal segmental glomerulosclerosis: a HuGE review. Genet Med 8:63–75

65. Pereira AC, Pereira AB, Mota GF, Cunha RS, Herkenhoff FL, Pollak MR, Mill JG, Krieger JE (2004) NPHS2 R229Q functional variant is associated with microalbuminuria in the general population. Kidney Int 65:1026–1030

66. Kottgen A, Hsu CC, Coresh J, Shuldiner AR, Berthier-Schaad Y, Pereira AC, Pereira AB, Mota GF, Cunha RS, Herkenhoff FL, Pollak MR, Mill JG, Krieger JE (2004) NPHS2 R229Q functional variant is associated with microalbuminuria in a large population-based sample of US adults. Am J Kidney Dis 52:868–875

67. Santin S, Garcia-Maset R, Ruiz P, Gimenez I, Zamora I, Pena A, Madrid A, Camacho JA, Fraga G, Sanchez-Moreno A, Cobo MA, Bernis C, Ortiz A, de Pablos AL, Pintos G, Justa ML, Hidalgo-Barquero E, Fernández-Llama P, Ballarin J, Ars E, Torra R (2009) Nephrin mutations cause childhood- and adult-onset focal segmental glomerulosclerosis. Kidney Int 76:1268–1276

68. Kitamura A, Tsukaguchi H, Hiramoto R, Shono A, Doi T, Kaga M, Iijima K (2007) A familial childhood-onset relapsing nephrotic syndrome. Kidney Int 71:946–951

69. Lowik M, Levitchenko E, Westra D, Groenen P, Steenbergen E, Weening J, Lilien M, Monnens L, van den Heuvel L (2008) Bigenic heterozygosity and the development of steroid-resistant focal segmental glomerulosclerosis. Pediatr Nephrol 23:3146–3151

70. Gbadebesin R, Bartkowiak B, Lavin PJ, Mukerji N, Wu G, Bowling B, Eckel J, Damodaran T, Winn MP (2009) Exclusion of homozygous PLCε1 (NPHS3) mutations in 69 families with steroid-resistant focal segmental glomerulosclerosis. Pediatr Nephrol 24:281–285

71. Jeanpierre C, Denamur E, Henry I, Cabanis MO, Luce S, Cecille A, Eliou J, Peuchmaur M, Loirat C, Niaudet P, Gubler MC, Junien C (1999) Identification of constitutional WT1 mutations, in patients with isolated diffuse mesangial sclerosis, and analysis of genotype/phenotype correlations by use of a computerized mutation database. Am J Hum Genet 62:824–833

72. Demmer L, Primack W, Loik V, Brown R, Therville N, McElreavey K (1999) Frasier syndrome: a cause of focal segmental glomerulosclerosis in a 46, XX female. J Am Soc Nephrol 10:2215–2218

73. Denamur E, Bocquet N, Mougenot B, Da Silva F, Martinat L, Loirat C, Eliou J, Bensman A, Ronco PM (1999) Identification of constitutional WT1 splice-site mutation is responsible for distinct glomerular diseases. J Am Soc Nephrol 10:2219–2223

74. Rau RG, Schultheiss M, Lichtenberger A, Karle SM, Zalewski I, Mucha B, Everding AS, Neuhauß T, Patzer L, Plank C, Haas JP, Ozaltin F, Imm A, Fuchshuber A, Bakkaloglu A, Hildebrandt F (2004) Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome. Kidney Int 66:564–570

75. Lowik MM, Groenen PJ, Pronk I, Lilien MR, Goldschmeding R, Dijkmans HB, Levitchenko EN, Monnens LA, van den Heuvel LP (2007) Focal segmental glomerulosclerosis in a patient homozygous for a CD2AP mutation. Kidney Int 72:1198–1203

76. Benoit G, Machuca E, Nevo F, Gribouval O, Lepage D, Antignac C (2010) Analysis of recessive CD2AP and ACTN4 mutations in steroid-resistant nephrotic syndrome. Pediatr Nephrol 25:445–451

77. Gigante M, Pontrelli P, Montemurro E, Roca L, Aucella F, Penza R, Caridi G, Ranieri E, Ghiglieri GM, Gesualdo L (2009) CD2AP mutations are associated with sporadic nephrotic syndrome and focal segmental glomerulosclerosis (FSGS). Nephrol Dial Transplant 24:1858–1864

78. Weins A, Kenlan P, Herbert S, Le TC, Villegas I, Kaplan BS, Appel GB, Pollak MR (2005) Mutational and biological analysis of alpha-actinin-4 in focal segmental glomerulosclerosis. J Am Soc Nephrol 16:3694–3701

79. Santin S, Ars E, Rossetti S, Salido E, Silva I, Garcia-Maset R, Gimenez I, Ruiz P, Mendizabal S, Luciano Nieto J, Pena A, Camacho JA, Fraga G, Cobo MA, Bernis C, Ortiz A, de Pablos AL, Pintos G, Justa ML, Hidalgo E, de Frutos DB, Trillo E, Gracia S, de los Rios FJ (2009) TRPC6 mutation analysis in a large cohort of patients with focal segmental glomerulosclerosis. Nephrol Dial Transplant 24:3089–3096

80. Pollak MR, Alexander MP, Henderson JM (2007) A case of familial kidney disease. Clin J Am Soc Nephrol 2:1367–1374

81. Reiser J, Polu KR, Moller CC, Kenlan P, Altintas MM, Wei C, Faul C, Herbert S, Villegas I, Avila-Casado C, Mcgee M, Sugimoto H, Brown D, Kalluri R, Mundel P, Smith PL, Clapham DE, Pollak MR (2005) TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet 37:739–744

82. Choi HJ, Lee BH, Cho HY, Moon KC, Ha IS, Nagata M, Choi Y, Cheong HI (2008) Familial focal segmental glomerulosclerosis associated with an ACTN4 mutation and paternal germline mosaicism. Am J Kidney Dis 51:834–838

83. Heeringa SF, Moller CC, Du J, Yue L, Hinkes B, Chernin G, Vlangos CN, Hoyer PF, Reiser J, Hildebrandt F (2009) A novel TRPC6 mutation that causes childhood FSGS. J Am Soc Nephrol 16:3694–3701

84. Patrakka J, Martin P, Salonen R, Kestila M, Ruotsalainen V, Heeringa SF, Moller CC, Du J, Yue L, Hinkes B, Chernin G, Vlangos CN, Hoyer PF, Reiser J, Hildebrandt F (2009) A novel TRPC6 mutation that causes childhood FSGS. PLoS One 4: e7771

85. Badaracco I, Martini P, Salonen R, Kestila M, Ruotsalainen V, Maniakko M, Rynnannen M, Rapola J, Holmgren C, Tryggvason K, Jalkano H (2002) Proteinuria and prenatal diagnosis of congenital nephrosis in fetal carriers of nephrin gene mutations. Lancet 359:1575–1577

86. Devriendt K, van den Berghe K, Moerman P, Fryns JP (1996) Elevated maternal serum and amniotic fluid alpha-fetoprotein levels in the Denys–Drash syndrome. Prenat Diagn 16:455–457

87. Malina M, Cinek O, Janda J, Seeman T (2009) Partial remission with cyclosporine A in a patient with nephrotic syndrome due to NPHS2 mutation. Pediatr Nephrol 24:2051–2053

88. Artero M, Biava C, Amend W, Tomlanovich S, Vincenti F (1992) Recurrent focal glomerulosclerosis: natural history and response to therapy. Am J Med 92:375–383

89. Dal'Amico R, Ghiggeri GM, Carraro M, Artero M, Ghio L, Dall'Amico R, Ghiggeri G, Carraro M, Artero M, Ghio L, Dall'Amico R, Ghiggeri GM, Carraro M, Artero M, Ghio L (2009) Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. Am J Kidney Dis 54:1048–1055

90. Ingulli E, Tejani A (1991) Incidence, treatment, and outcome of recurrent focal segmental glomerulosclerosis posttransplantation in 42 allografts in children—a single-center experience. Transplantation 51:401–405
90. Becker-Cohen R, Bruschi M, Rinat C, Feinstein S, Zennaro C, Ghiggeri GM, Frishberg Y (2007) Recurrent nephrotic syndrome in homozygous truncating NPHS2 mutation is not due to anti-podocin antibodies. Am J Transplant 7:256–260

91. Bertelli R, Ginevri F, Caridi G, Dagnino M, Sandrini S, Di Duca M, Emma F, Sanna-Cherchi S, Scolari F, Neri TM, Murer L, Massella L, Basile G, Rizzoni G, Perfumo F, Ghiggeri GM (2003) Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin. Am J Kidney Dis 41:1314–1321

92. Billing H, Muller D, Ruf R, Lichtenberger A, Hildebrandt F, August C, Querfeld U, Haffner D (2004) NPHS2 mutation associated with recurrence of proteinuria after transplantation. Pediatr Nephrol 19:561–564

93. Carraro M, Caridi G, Bruschi M, Artero M, Bertelli R, Zennaro C, Musante L, Candiano G, Perfumo F, Ghiggeri GM (2002) Serum glomerular permeability activity in patients with podocin mutations (NPHS2) and steroid-resistant nephrotic syndrome. J Am Soc Nephrol 13:1946–1952

94. Hocker B, Knuppel T, Waldherr R, Schaefer F, Weber S, Tonshoff B (2006) Recurrence of proteinuria 10 years post-transplant in NPHS2-associated focal segmental glomerulosclerosis after conversion from cyclosporin A to sirolimus. Pediatr Nephrol 21:1476–1479

95. Ghiggeri GM, Aucella F, Caridi G, Bisceglia L, Ghio L, Gigante M, Perfumo F, Carrafo M, Gesualdo L (2006) Posttransplant recurrence of proteinuria in a case of focal segmental glomerulosclerosis associated with WT1 mutation. Am J Transplant 6:2208–2211

96. Patrakka J, Ruotsalainen V, Reponen P, Qvist E, Laine J, Holmberg C, Tryggvason K, Jalanko H (2002) Recurrence of nephrotic syndrome in kidney grafts of patients with congenital nephrotic syndrome of the Finnish type: role of nephrin. Transplantation 73:394–403

97. Flynn JT, Schulman SL, deChadarevian JP, Dunn SP, Kaiser BA, Polinsky MS, Baluarte HJ (1992) Treatment of steroid-resistant post-transplant nephrotic syndrome with cyclophosphamide in a child with congenital nephrotic syndrome. Pediatr Nephrol 6:553–555

98. Caridi G, Dagnino M, Sanna-Cherchi S, Perfumo F, Ghiggeri GM (2006) Podocin-related mechanisms in posttransplant recurrence of focal segmental glomerulosclerosis. Transplant Proc 38:3486–3490

99. Di Duca M, Oleggini R, Sanna-Cherchi S, Pasquali L, Di Donato A, Parodi S, Bertelli R, Caridi G, Frasca G, Cerullo G, Amoroso A, Schena FP, Scolari F, Ghiggeri GM (2006) Cis and trans regulatory elements in NPHS2 promoter: implications in proteinuria and progression of renal diseases. Kidney Int 70:1332–1341

100. Freedman BI, Nagaraj SK, Lin JJ, Gautreaux MD, Bowden DW, Iskandar SS, Stratta RJ, Rogers J, Hartmann EL, Farney AC, Reeves-Daniel AM (2009) Potential donor-recipient MYH9 genotype interactions in posttransplant nephrotic syndrome after pediatric kidney transplantation. Am J Transplant 9:2435–2440

101. Maruyama K, Iijima K, Ikeda M, Kitamura A, Tsukaguchi H, Yoshiya K, Hoshi S, Wada N, Uemura O, Satomura K, Honda M, Yoshikawa N (2003) NPHS2 mutations in sporadic steroid-resistant nephrotic syndrome in Japanese children. Pediatr Nephrol 18:412–416